Related Experiment Video
Updated: Jan 29, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Antibacterial Activity of Bacteriophage Lytic Enzyme Ply900
Yuan Li1, Luxiang Xu1, Yuhan Zhang1
1College of Veterinary Medicine (Preventive Veterinary Medicine), Northeast Agricultural University, No. 600, Changjiang Road, Xiangfang District, Harbin 150030, China.
Abstract:
S. suis is a prominent zoonotic pathogen responsible for diseases such as arthritis in piglets, swine septicemia, and meningitis. The emergence of multi-drug resistance (MDR) underscores the urgent need for the development of novel antibacterial strategies. In this context, a systematic evaluation of the antibacterial potential of the bacteriophage lytic enzyme Ply900 was conducted in this study, along with an analysis of its domain functions and an in vivo study of its therapeutic dynamics. Ply900 exhibits potent in vitro lytic activity against multiple bacteria, including Streptococcus suis, Streptococcus agalactiae, and Staphylococcus aureus. Notably, it possesses broad biochemical stability, with tolerance to diverse environmental conditions. In a mouse model of S. suis serotype 2 SC19 infection, both the direct Ply900 treatment group and the triple therapy group achieved effective eradication of S. suis, with markedly improved survival rates. The remaining bacteria remained susceptible to Ply900, with no evidence of induced resistance development. Mechanistic analysis revealed that the SH3B domain of Ply900 enhances targeted cleavage efficiency by binding synergistically to peptidoglycan with the CHAP domain, with CYS-34, HIS-59, and ASP-28 serving as key amino acid sites for Ply900's cleavage activity. Collectively, these findings lay the foundation for the potential dual applications of the lysin Ply900, both in the clinical treatment of S. suis infections and in the prevention and control of these pathogenic bacteria in livestock farming.
Insights
The bacteriophage lytic enzyme Ply900 effectively combats Streptococcus suis infections in mice, showing broad antibacterial activity and stability. This lysin offers a promising new strategy against multi-drug resistant bacterial pathogens.
Area of Science:
- Microbiology
- Bacteriophage Therapy
- Antimicrobial Resistance
Background:
- Streptococcus suis (S. suis) is a significant zoonotic pathogen causing severe diseases in both animals and humans.
- The rise of multi-drug resistance (MDR) in bacteria necessitates the development of alternative antibacterial treatments.
- Bacteriophage-derived lysins represent a promising class of antimicrobials.
Purpose of the Study:
- To evaluate the antibacterial potential and therapeutic efficacy of the bacteriophage lytic enzyme Ply900 against S. suis.
- To analyze the functional domains of Ply900 and elucidate its mechanism of action.
- To assess the in vivo therapeutic dynamics and resistance development potential of Ply900.
Main Methods:
- In vitro lytic activity assays against various bacterial strains.
- Biochemical stability tests under different environmental conditions.
- In vivo efficacy study using a mouse model of S. suis infection, including survival rate analysis.
- Mechanistic analysis of Ply900's domain functions and key amino acid residues involved in cleavage.
Main Results:
- Ply900 demonstrated potent lytic activity against S. suis, S. agalactiae, and S. aureus.
- The enzyme exhibited broad biochemical stability, tolerating diverse conditions.
- In vivo studies showed effective S. suis eradication and improved survival rates in infected mice.
- No induced resistance to Ply900 was observed in the treated bacterial populations.
- The SH3B and CHAP domains were identified as crucial for synergistic peptidoglycan binding and cleavage.
Conclusions:
- Lysin Ply900 is a potent antibacterial agent with broad-spectrum activity and stability.
- Ply900 demonstrates significant therapeutic potential for treating S. suis infections in vivo.
- The enzyme's mechanism involves synergistic domain interactions, and no resistance was induced, highlighting its promise for clinical and agricultural applications.
Related Concept Videos
Lytic Cycle of Bacteriophages
Lysogenic Cycle of Bacteriophages
Enzymes and Activation Energy
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
DNA Bacteriophages
Enzyme Kinetics
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...

